200 related articles for article (PubMed ID: 22486368)
1. Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space.
Rabal O; Oyarzabal J
J Chem Inf Model; 2012 May; 52(5):1086-102. PubMed ID: 22486368
[TBL] [Abstract][Full Text] [Related]
2. Biologically relevant chemical space navigator: from patent and structure-activity relationship analysis to library acquisition and design.
Rabal O; Oyarzabal J
J Chem Inf Model; 2012 Dec; 52(12):3123-37. PubMed ID: 23176522
[TBL] [Abstract][Full Text] [Related]
3. Bioactivity-guided navigation of chemical space.
Bon RS; Waldmann H
Acc Chem Res; 2010 Aug; 43(8):1103-14. PubMed ID: 20481515
[TBL] [Abstract][Full Text] [Related]
4. GLIDA: GPCR-ligand database for chemical genomic drug discovery.
Okuno Y; Yang J; Taneishi K; Yabuuchi H; Tsujimoto G
Nucleic Acids Res; 2006 Jan; 34(Database issue):D673-7. PubMed ID: 16381956
[TBL] [Abstract][Full Text] [Related]
5. Expanding the medicinally relevant chemical space with compound libraries.
López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
[TBL] [Abstract][Full Text] [Related]
6. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors.
Nettles JH; Jenkins JL; Bender A; Deng Z; Davies JW; Glick M
J Med Chem; 2006 Nov; 49(23):6802-10. PubMed ID: 17154510
[TBL] [Abstract][Full Text] [Related]
7. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?
Bender A; Jenkins JL; Glick M; Deng Z; Nettles JH; Davies JW
J Chem Inf Model; 2006; 46(6):2445-56. PubMed ID: 17125186
[TBL] [Abstract][Full Text] [Related]
8. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery.
Pérot S; Sperandio O; Miteva MA; Camproux AC; Villoutreix BO
Drug Discov Today; 2010 Aug; 15(15-16):656-67. PubMed ID: 20685398
[TBL] [Abstract][Full Text] [Related]
9. Drug design strategies for targeting G-protein-coupled receptors.
Klabunde T; Hessler G
Chembiochem; 2002 Oct; 3(10):928-44. PubMed ID: 12362358
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields.
Durán A; Martínez GC; Pastor M
J Chem Inf Model; 2008 Sep; 48(9):1813-23. PubMed ID: 18693718
[TBL] [Abstract][Full Text] [Related]
11. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
Deng Z; Chuaqui C; Singh J
J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
[TBL] [Abstract][Full Text] [Related]
12. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
Heilker R; Wolff M; Tautermann CS; Bieler M
Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
[TBL] [Abstract][Full Text] [Related]
13. Flexible 3D pharmacophores as descriptors of dynamic biological space.
Nettles JH; Jenkins JL; Williams C; Clark AM; Bender A; Deng Z; Davies JW; Glick M
J Mol Graph Model; 2007 Oct; 26(3):622-33. PubMed ID: 17395510
[TBL] [Abstract][Full Text] [Related]
14. Similarity metrics for ligands reflecting the similarity of the target proteins.
Schuffenhauer A; Floersheim P; Acklin P; Jacoby E
J Chem Inf Comput Sci; 2003; 43(2):391-405. PubMed ID: 12653501
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based ligand discovery.
Fischer M; Hubbard RE
Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
[TBL] [Abstract][Full Text] [Related]
16. Strategies for designing GPCR-focused libraries and screening sets.
Jimonet P; Jäger R
Curr Opin Drug Discov Devel; 2004 May; 7(3):325-33. PubMed ID: 15216936
[TBL] [Abstract][Full Text] [Related]
17. Using chiral molecules as an approach to address low-druggability recognition sites.
Lucas X; Günther S
J Comput Chem; 2014 Nov; 35(29):2114-21. PubMed ID: 25223950
[TBL] [Abstract][Full Text] [Related]
18. Large-scale similarity search profiling of ChEMBL compound data sets.
Heikamp K; Bajorath J
J Chem Inf Model; 2011 Aug; 51(8):1831-9. PubMed ID: 21728295
[TBL] [Abstract][Full Text] [Related]
19. Ligand-based approach to in silico pharmacology: nuclear receptor profiling.
Mestres J; Martín-Couce L; Gregori-Puigjané E; Cases M; Boyer S
J Chem Inf Model; 2006; 46(6):2725-36. PubMed ID: 17125212
[TBL] [Abstract][Full Text] [Related]
20. Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.
Fauman EB; Rai BK; Huang ES
Curr Opin Chem Biol; 2011 Aug; 15(4):463-8. PubMed ID: 21704549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
